Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 9/20 | 0.58 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.58 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CBS | P35520 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12398427 | 0.77 | DAGLA (0.59) | CES1DAGLANCEH1MAPTRXFP1 | |
| SCHEMBL8559822 | 0.74 | TDP1 (0.85) | CES1MAPTRXFP1ACHESGMS1 | |
| SCHEMBL9242650 | 0.74 | TDP1 (0.85) | CES1MAPTRXFP1ACHESGMS1 | |
| SCHEMBL7426101 | 0.74 | TDP1 (0.85) | CES1MAPTRXFP1ACHESGMS1 | |
| SCHEMBL2161875 | 0.73 | CES1 (1.00) | CES1DAGLANCEH1MAPTRXFP1 | |
| SCHEMBL2161990 | 0.72 | CES1 (1.00) | CES1DAGLANCEH1FAAH | |
| SCHEMBL3070677 | 0.72 | TDP1 (0.89) | CES1MAPTRXFP1ACHESGMS1 | |
| SCHEMBL31752166 | 0.72 | NPC1 (0.54) | CES1DAGLANCEH1FAAH | |
| SCHEMBL503837 | 0.71 | MAPT (1.00) | CES1MAPTRXFP1FAAH | |
| SCHEMBL1008045 | 0.71 | MAPT (1.00) | CES1MAPTRXFP1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | claimed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | claimed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987312-B2 | Alpha-keto heterocycles as FAAH inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-03-24 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010005572-A2 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | CES1 11/4885DAGLA 289/4885NCEH1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.